The global clostridium difficile infection treatment market is anticipated to grow at a CAGR of around 5.8% during the forecast period 2020 to 2027 and to reach around US$ 1.4 Bn by 2027.
Market Dynamics
Major factors expected to drive the growth of the global market are increasing number of patients suffering from chronic diseases, coupled with introduction of innovative treatment from major players. According to U.S. Department of Health & Human Services in 2017, there were an estimated 223,900 cases in hospitalized patients suffering from clostridioides difficile infection and 12,800 deaths in the United States.
Government of developing countries focus on enhancing the healthcare R&D capabilities is resulting in adoption of advanced equipments along with high spending on drug discovery in order to provide novel drugs. Developing healthcare standards and high spending on infrastructure development in order to facilitate the adoption of advanced treatment is expected to boost the growth of target market.
In 2018, Xellia Pharmaceuticals, a leader in manufacturing of specialty anti-infective treatments launched Vancomycin Hydrochloride for Injection in the US market. This product launch is expected to help the company to strengthen its position in US market.
In 2016, Baxter International Inc. a global drug manufacturer launched VANCOMYCIN a ready-to-use injection in 0.9% Sodium Chloride. VANCOMYCIN injection is an antibiotic used to treat serious or severe bacterial infections. This is expected to help the company to enhance the customer base.
In 2017, Astellas Pharma Inc. a global drug company announced that it has sent approval for marketing of fidaxomicin that is for the treatment of infectious enteritis. This is expected to help the company to attract new customer and enhance the customer base.
In 2018, the company announced the launch of Dafclir® Tablets for the Treatment of Infectious Enteritis. This is an oral macrocyclic antimicrobial agent with a new mechanism of action and a selective antibacterial spectrum. This will help the company to increase the revenue share.
Increasing merger and acquisition activities by major players in order to strengthen its business presence and enhance the product portfolio are factors expected to positively impact the growth of target market. In addition, increasing public-private partnership for R&D activities is expected to support the growth of target market.
In 2017, Xellia Pharmaceuticals a pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, invested US$ 25 Mn for the expansion of its Copenhagen site. This is expected to help the company to enhance its product capabilities.
Flourishing healthcare sector in countries such as Singapore and Malaysia along with availability of advanced medical facilities at low cost and favorable insurance policies are factors expected to support the growth of target market.
However, factors such as high cost associated to R&D activities and stringent government regulation related to product approval are expected to hamper the growth of global clostridium difficile infection treatment market. In addition, low awareness related to CDI in developing countries is expected to challenge the growth of target market.
Rapid technological advancements by major players and introduction of novel treatments are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and agreements between regional and international players is expected to revenue support the growth of target market.
Segment Analysis by Region
The market in North America is expected to account for significant revenue share owing to increasing number of patients suffering from chronic diseases. In addition presence of large number of players operating in the country and focus on introduction of innovative solution are factors expected to support the growth of target market.
Competitive Landscape
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Report coverage
|
Market
|
Global Clostridium Difficile Infection Treatment Market
|
|
Analysis Period
|
2016 – 2027
|
|
Base Year
|
2019
|
|
Forecast Data
|
2020 – 2027
|
|
Market Stratification
|
Drug Type, Administration, Distribution Channel and Geography
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
|
Clostridium Difficile Infection Treatment Market Segment Analysis, 2019
The global clostridium difficile infection treatment market is segmented into drug type, administration, and distribution channel. The administration segment is bifurcated into oral and injectable. Among administration the injectable segment is expected to witness faster growth in the near future due to high R&D activities by major players are introduction of innovative solutions. The distribution channel segment is divided into hospital pharmacies, retail pharmacies, and others. The hospital segment is expected to account for major revenue share in the global market. This is due to high government spending on development of hospital infrastructure.
The players profiled in the report are Baxter International Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd, Mylan, Novartis AG, Astellas Pharma, Merck and Co. Inc., Pfizer Inc., Eli Lilly and Company, AstraZeneca Plc.
Market Segmentation
Market By Drug Type
Vancomycin
Fidaxomicin
Metronidazole
Market By Administration
Oral
Injectable
Market By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Market By Region
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Clostridium Difficile Infection Treatment
1.1. Definition and Scope
1.1.1. Definition of Clostridium Difficile Infection Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Clostridium Difficile Infection Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Clostridium Difficile Infection Treatment Market By Drug Type
1.2.3. Clostridium Difficile Infection Treatment Market By Administration
1.2.4. Clostridium Difficile Infection Treatment Market By Distribution Channel
1.2.5. Clostridium Difficile Infection Treatment Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Clostridium Difficile Infection Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Clostridium Difficile Infection Treatment Market
3.7. Value Chain Analysis
3.8. Cost Structure Analysis
3.8.1. Proportion of Manufacturing Cost Structure
3.8.1.1. Raw Material
3.8.1.2. Labor Cost
3.8.1.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Clostridium Difficile Infection Treatment Market By Drug Type
4.1. Introduction
4.2. Clostridium Difficile Infection Treatment Revenue By Drug Type
4.2.1. Clostridium Difficile Infection Treatment Revenue (US$ Mn) and Forecast, By Drug Type, 2016-2027
4.2.2. Vancomycin
4.2.2.1. Vancomycin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.3. Fidaxomicin
4.2.3.1. Fidaxomicin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.4. Metronidazole
4.2.4.1. Metronidazole Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 5. Clostridium Difficile Infection Treatment Market Revenue By Administration
5.1. Introduction
5.2. Clostridium Difficile Infection Treatment Revenue (US$ Mn) By Administration
5.2.1. Clostridium Difficile Infection Treatment Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
5.2.2. Oral
5.2.2.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Injectable
5.2.3.1. Injectable Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Clostridium Difficile Infection Treatment Market By Distribution Channel
6.1. Introduction
6.2. Clostridium Difficile Infection Treatment Revenue (US$ Mn) By Distribution Channel
6.2.1. Clostridium Difficile Infection Treatment Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
6.2.2. Hospital Pharmacies
6.2.2.1. Hospital Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Retail Pharmacies
6.2.3.1. Retail Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Others
6.2.4.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. North America Clostridium Difficile Infection Treatment Market By Country
7.1. North America Clostridium Difficile Infection Treatment Overview
7.2. U.S.
7.2.1. U.S. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
7.2.2. U.S. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
7.2.3. U.S. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
7.3. Canada
7.3.1. Canada Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
7.3.2. Canada Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
7.3.3. Canada Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
7.4. North America PEST Analysis
CHAPTER 8. Europe Clostridium Difficile Infection Treatment Market By Country
8.1. Europe Clostridium Difficile Infection Treatment Market Overview
8.2. U.K.
8.2.1. U.K. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
8.2.2. U.K. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
8.2.3. U.K. Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.3. Germany
8.3.1. Germany Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
8.3.2. Germany Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
8.3.3. Germany Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.4. France
8.4.1. France Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
8.4.2. France Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
8.4.3. France Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.5. Spain
8.5.1. Spain Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
8.5.2. Spain Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
8.5.3. Spain Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.6. Rest of Europe
8.6.1. Rest of Europe Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016-2027
8.6.2. Rest of Europe Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016-2027
8.6.3. Rest of Europe Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Clostridium Difficile Infection Treatment Market By Country
9.1. Asia Pacific Clostridium Difficile Infection Treatment Market Overview
9.2. China
9.2.1. China Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.2.2. China Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.2.3. China Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.3. Japan
9.3.1. Japan Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.3.2. Japan Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.3.3. Japan Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.4. India
9.4.1. India Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.4.2. India Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.4.3. India Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.5. Australia
9.5.1. Australia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.5.2. Australia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.5.3. Australia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.6. South Korea
9.6.1. South Korea Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.6.2. South Korea Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.6.3. South Korea Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
9.7.2. Rest of Asia-Pacific Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
9.7.3. Rest of Asia-Pacific Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Clostridium Difficile Infection Treatment Market By Country
10.1. Latin America Clostridium Difficile Infection Treatment Market Overview
10.2. Brazil
10.2.1. Brazil Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
10.2.2. Brazil Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
10.2.3. Brazil Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.3. Mexico
10.3.1. Mexico Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
10.3.2. Mexico Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
10.3.3. Mexico Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.4. Rest of Latin America
10.4.1. Rest of Latin America Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
10.4.2. Rest of Latin America Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 – 2027
10.4.3. Rest of Latin America Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 – 2027
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Clostridium Difficile Infection Treatment Market By Country
11.1. Middle East & Africa Clostridium Difficile Infection Treatment Market Overview
11.2. Saudi Arabia
11.2.1. Saudi Arabia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
11.2.2. Saudi Arabia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
11.2.3. Saudi Arabia Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.3. UAE
11.3.1. UAE Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
11.3.2. UAE Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
11.3.3. UAE Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Drug Type, 2016 - 2027
11.4.2. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Administration, 2016 - 2027
11.4.3. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 – 2027
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Clostridium Difficile Infection Treatment
12.1. Clostridium Difficile Infection Treatment Market Company Share Analysis
12.2. Mergers And Acquisition In Global Clostridium Difficile Infection Treatment Market
CHAPTER 13. COMPANY PROFILE
13.1. Baxter International Inc.
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Mn), 2019
13.1.3.2. Baxter International Inc. 2019 Clostridium Difficile Infection Treatment Business Regional Distribution
13.1.4. Product/ Service and Specification
13.1.5. Manufacturing Plant Footprint Analysis
13.2. Sanofi S.A.
13.3. Actelion Pharmaceuticals Ltd
13.4. Mylan
13.5. Novartis AG
13.6. Astellas Pharma
13.7. Merck and Co. Inc.
13.8. Pfizer Inc.
13.9. Eli Lilly
13.10. AstraZeneca Plc
13.11. Others
